Status:
TERMINATED
A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery
Lead Sponsor:
Virtua Health, Inc.
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Postoperative Nausea and Vomiting
Respiratory Conditions Due to Other External Agents
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
The investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiti...
Detailed Description
During their preadmission testing, patients planning to undergo sleeve gastrectomy bariatric surgeries will be consented (by having them sign consent forms) and recruited for the study. A trained indi...
Eligibility Criteria
Inclusion
- Patients having sleeve gastrectomy
- Surgeries performed by a particular surgeon - Dr. Sam Wasser
- Body Mass Index greater than 35
- American Society of Anesthesiologists Score II and III patients
Exclusion
- Patients having a different type of bariatric surgery including but not limited to duodenal switch, gastric bypass, hand-assisted laparoscopic sleeve gastrectomy
- Sleeve gastrectomy's performed by other surgeons than Dr. Sam Wasser.
- Pregnancy
- Allergic to sugammadex, Zofran or scopolamine
- Chronic Obstructive Pulmonary Disease or Asthma that is uncontrolled
- American Society of Anesthesiologists Score I, IV, V patients
Key Trial Info
Start Date :
February 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2018
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT03276026
Start Date
February 12 2018
End Date
November 8 2018
Last Update
May 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virtua Memorial Hospital
Mount Holly, New Jersey, United States, 08060